Article

CD8+ T-Lymphocyte Response to Major Immunodominant Epitopes after Vaginal Exposure to Simian Immunodeficiency Virus: Too Late and Too Little

Wisconsin Primate Research Center, University of Wisconsin, Madison 53715, USA.
Journal of Virology (Impact Factor: 4.65). 08/2005; 79(14):9228-35. DOI: 10.1128/JVI.79.14.9228-9235.2005
Source: PubMed

ABSTRACT In the acute stage of infection following sexual transmission of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), virus-specific CD8+ T-lymphocyte responses partially control but do not eradicate infection from the lymphatic tissues (LTs) or prevent the particularly massive depletion of CD4+ T lymphocytes in gut-associated lymphatic tissue (GALT). We explored hypothetical explanations for this failure to clear infection and prevent CD4+ T-lymphocyte loss in the SIV/rhesus macaque model of intravaginal transmission. We examined the relationship between the timing and magnitude of the CD8+ T-lymphocyte response to immunodominant SIV epitopes and viral replication, and we show first that the failure to contain infection is not because the female reproductive tract is a poor inductive site. We documented robust responses in cervicovaginal tissues and uterus, but only several days after the peak of virus production. Second, while we also documented a modest response in the draining genital and peripheral lymph nodes, the response at these sites also lagged behind peak virus production in these LT compartments. Third, we found that the response in GALT was surprisingly low or undetectable, possibly contributing to the severe and sustained depletion of CD4+ T lymphocytes in the GALT. Thus, the virus-specific CD8+ T-lymphocyte response is "too late and too little" to clear infection and prevent CD4+ T-lymphocyte loss. However, the robust response in female reproductive tissues may be an encouraging sign that vaccines that rapidly induce high-frequency CD8+ T-lymphocyte responses might be able to prevent acquisition of HIV-1 infection by the most common route of transmission.

Download full-text

Full-text

Available from: Christopher James Miller, Aug 20, 2015
1 Follower
 · 
84 Views
  • Source
    • "Interestingly, few virus-specific CTLs were detected in the gut of vaginally inoculated animals using similar (tetramer) techniques (Reynolds et al. 2005), which could reflect differences in CTL development or homing depending on the route of transmission, but this remains to be fully explored. In addition to cell-mediated immune responses, infection with SIV or HIV also results in generation of diverse antibody responses, although some strains of SIV are quite poor at eliciting neutralizing antibodies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus (HIV) pathogenesis has proven to be quite complex and dynamic with most of the critical events (e.g., transmission, CD4(+) T-cell destruction) occurring in mucosal tissues. In addition, although the resulting disease can progress over years, it is clear that many critical events happen within the first few weeks of infection when most patients are unaware that they are infected. These events occur predominantly in tissues other than the peripheral blood, particularly the gastrointestinal tract, where massive depletion of CD4(+) T cells occurs long before adverse consequences of HIV infection are otherwise apparent. Profound insights into these early events have been gained through the use of nonhuman primate models, which offer the opportunity to examine the early stages of infection with the simian immunodeficiency virus (SIV), a close relative of HIV that induces an indistinguishable clinical picture from AIDS in Asian primate species, but importantly, fails to cause disease in its natural African hosts, such as sooty mangabeys and African green monkeys. This article draws from data derived from both human and nonhuman primate studies.
    Cold Spring Harbor Perspectives in Medicine 09/2012; 2(9). DOI:10.1101/cshperspect.a007005 · 7.56 Impact Factor
  • Source
    • "The conventional anamnestic expansiondependent central memory T-cell type of vaccine responses induced by these vaccines typically were unable to provide truly effective, sustained control of viral replication (Reynolds et al. 2005). To test the hypothesis that a qualitatively different type of immune response might be more effective, persistent rhesus cytomegalovirus-based vectors expressing most of the SIV genome were explored and elicited strong, broad, persistent CD4þ and CD8þ effector memory T-cell responses that were associated with stringent control of replication following repeated titered intrarectal challenge with SIV- mac239 (Hansen et al. 2009, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonhuman primate (NHP) disease models for AIDS have made important contributions to the search for effective vaccines for AIDS. Viral diversity, persistence, capacity for immune evasion, and safety considerations have limited development of conventional approaches using killed or attenuated vaccines, necessitating the development of novel approaches. Here we highlight the knowledge gained and lessons learned in testing vaccine concepts in different virus/NHP host combinations.
    Cold Spring Harbor Perspectives in Medicine 06/2012; 2(6):a007310. DOI:10.1101/cshperspect.a007310 · 7.56 Impact Factor
  • Source
    • "In ,2 wk, a very small founder population of productively infected cells at the portal of entry progresses to systemic infection with a burst of virus production and depletion of gut CD4 þ T cells. At this point, a robust virus-specific immune response can contain viral replication only to a certain degree (Reynolds et al. 2005). Thus, the first days of infection at the mucosa when replication is limited to small clusters of infected cells are the periods of maximum virus vulnerability and represent a window of opportunity for intervention. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The impressive advances in antiretroviral (ARV) therapy of chronic human immunodeficiency virus (HIV) infections during the last decade and the availability of potent ARV drugs have fueled interest in using chemoprophylaxis as a novel HIV prevention strategy. Preexposure prophylaxis (PrEP) refers to the use of ARV drugs in HIV-negative persons to prevent HIV infection. The rationale for PrEP builds on the success of ARV prophylaxis in preventing mother-to-child transmission of HIV and on a large body of animal studies that show the efficacy of PrEP against mucosal and parenteral infection. We focus on oral administration of ARV drugs for prevention of HIV infection. Identifying an effective prophylactic pill that individuals can take outside the setting of sexual intercourse precludes the necessity to disclose such use to their partners, thereby empowering those who might not be in a position to negotiate with their partners. Several human clinical trials evaluating the efficacy of daily regimens of the HIV reverse-transcriptase (RT) inhibitors tenofovir disoproxil fumarate (TDF) or Truvada (TDF and emtricitabine [FTC]) are under way among high-risk populations. The results of one trial among men who have sex with men showed that daily Truvada was safe and effective, providing the first support for oral PrEP as a prevention strategy. Here we outline the preclinical and clinical research on oral PrEP, pharmacologic considerations, and future directions and challenges.
    Cold Spring Harbor Perspectives in Medicine 03/2012; 2(3):a007419. DOI:10.1101/cshperspect.a007419 · 7.56 Impact Factor
Show more